{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:27:21Z","timestamp":1794324441661,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Faculdade De Medicina De S\u00e3o Jos\u00e9 Do Rio Preto","id":[{"id":"https:\/\/ror.org\/052e6h087","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Albuminuric chronic kidney disease (CKD) remains a high cardiorenal-risk state despite renin\u2013angiotensin system blockade and sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) therapy. Endothelin receptor antagonists (ERAs) reduce albuminuria, but clinical use is limited by fluid retention, edema, hemodilution, and concern for heart-failure decompensation. This review examines the testable hypothesis that SGLT2i background therapy may mitigate ERA-associated fluid retention and improve ERA usability in albuminuric CKD without compromising antiproteinuric efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review prioritizing human studies and practice-relevant data on selective endothelin A receptor antagonism in albuminuric CKD, emphasizing quantitative efficacy signals, fluid retention, heart-failure risk, SGLT2i combination therapy, molecular mechanisms, and therapeutic sequencing and monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Available evidence supports a biologically coherent but not yet clinically established strategy. SONAR showed that atrasentan reduced kidney events in a responder-enriched population but retained a numerically higher heart-failure hospitalization signal. ZENITH-CKD showed that zibotentan added to dapagliflozin reduced urinary albumin-to-creatinine ratio at 12 weeks, with dose-sensitive fluid-retention events that were more favorable with lower-dose zibotentan. However, evidence remains short-term, agent-specific, and centered mainly on zibotentan plus dapagliflozin. Mechanistically, ERA-associated fluid retention probably reflects interacting tubular, neurohormonal, vascular-permeability, and hemodilution pathways, whereas SGLT2i mitigation may involve natriuresis, plasma-volume contraction, hemoconcentration, tubuloglomerular effects, and non-diuretic cardiovascular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined ERA\/SGLT2i therapy should be viewed as a mechanistically plausible and clinically testable positioning strategy, not an established treatment paradigm. Broader adoption requires confirmation of durable kidney benefit, cardiovascular safety, real-world feasibility, and reproducible tolerability across eGFR strata and congestion-prone CKD phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-026-07909-z","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:38:41Z","timestamp":1783485521000},"page":"2393-2405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor\u2013based Mitigation of Fluid Retention"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7247-4950","authenticated-orcid":false,"given":"Lucas Maciel de Almeida","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3774-604X","authenticated-orcid":false,"given":"Luiggi Kevin Virgino","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6051-1808","authenticated-orcid":false,"given":"Yan Roberth","family":"Delmiro Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5377-2442","authenticated-orcid":false,"given":"Guilherme Diniz","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4803-1546","authenticated-orcid":false,"given":"Nilson Hitoshi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"4S","key":"7909_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"12","key":"7909_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"issue":"15","key":"7909_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"7909_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"12","key":"7909_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2215\/CJN.0000000000000550","volume":"19","author":"D van Mil","year":"2024","unstructured":"van Mil D, Vart P, Chertow GM, et al. Baseline, early changes, and residual albuminuria: post hoc analysis of a randomized clinical trial of dapagliflozin in chronic kidney disease. Clin J Am Soc Nephrol. 2024;19(12):1574\u201384. https:\/\/doi.org\/10.2215\/CJN.0000000000000550.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"7909_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","volume":"151","author":"SE Claudel","year":"2025","unstructured":"Claudel SE, Verma A. Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review. Circulation. 2025;151(10):716\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071079.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"7909_CR7","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","volume":"40","author":"BL Neuen","year":"2025","unstructured":"Neuen BL, Yeung EK, Rangaswami J, Vaduganathan M. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol Dial Transpl. 2025;40(Suppl 1):i59\u201369. https:\/\/doi.org\/10.1093\/ndt\/gfae258.","journal-title":"Nephrol Dial Transpl"},{"issue":"23","key":"7909_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"7909_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10557-025-07698-x","volume":"40","author":"JY Chen","year":"2026","unstructured":"Chen JY, Pan HC, Wu VC. Association of angiotensin receptor-neprilysin inhibitors use and better cardiorenal outcomes in patients with heart failure and acute kidney disease. Cardiovasc Drugs Ther. 2026;40:251\u201362. https:\/\/doi.org\/10.1007\/s10557-025-07698-x.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7909_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10557-025-07744-8","volume":"40","author":"A Palani","year":"2026","unstructured":"Palani A, Patel S, Patel S, et al. GLP1-RA and SGLT2-i: implementation and insulin deescalation strategies. Cardiovasc Drugs Ther. 2026;40:779\u201393. https:\/\/doi.org\/10.1007\/s10557-025-07744-8.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7909_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10557-024-07588-8","volume":"39","author":"K Ichimura","year":"2025","unstructured":"Ichimura K, Gross A, Mathew RO, et al. Cardiorenal syndrome in right heart failure due to pulmonary arterial hypertension\u2014the right ventricle as a therapeutic target to improve renal function. Cardiovasc Drugs Ther. 2025;39:373\u201384. https:\/\/doi.org\/10.1007\/s10557-024-07588-8.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7909_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s10557-024-07646-1","volume":"39","author":"E Koutroumpakis","year":"2025","unstructured":"Koutroumpakis E, Patel R, Khadke S, et al. Associations of SGLT2i with cardiorenal outcomes among diabetics with prostate cancer on hormone therapy. Cardiovasc Drugs Ther. 2025;39:1343\u201352. https:\/\/doi.org\/10.1007\/s10557-024-07646-1.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7909_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10557-025-07714-0","volume":"40","author":"P Severino","year":"2026","unstructured":"Severino P, D\u2019Amato A, Myftari V, et al. Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology. Cardiovasc Drugs Ther. 2026;40:531\u201342. https:\/\/doi.org\/10.1007\/s10557-025-07714-0.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7909_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07800-3","author":"P Savage","year":"2025","unstructured":"Savage P, Linden K, Dixon L, Grieve D, Watson C. Investigation of biomarker response to SGLT2 inhibition in heart failure (SiN-HF). Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07800-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"7909_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.kint.2025.04.005","volume":"108","author":"A Ortiz","year":"2025","unstructured":"Ortiz A, Arreola Guerra JM, Chan JCN, et al. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108(4):555\u201371. https:\/\/doi.org\/10.1016\/j.kint.2025.04.005.","journal-title":"Kidney Int"},{"issue":"4","key":"7909_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1681\/ASN.2010080869","volume":"22","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763\u201372. https:\/\/doi.org\/10.1681\/ASN.2010080869.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"7909_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1681\/ASN.2013080830","volume":"25","author":"D de Zeeuw","year":"2014","unstructured":"de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083\u201393. https:\/\/doi.org\/10.1681\/ASN.2013080830.","journal-title":"J Am Soc Nephrol"},{"issue":"10184","key":"7909_CR18","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(19)30772-X.","journal-title":"Lancet"},{"issue":"6","key":"7909_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392(6):544\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2409415.","journal-title":"N Engl J Med"},{"issue":"3","key":"7909_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","volume":"21","author":"JFE Mann","year":"2010","unstructured":"Mann JFE, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527\u201335. https:\/\/doi.org\/10.1681\/ASN.2009060593.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"7909_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","volume":"35","author":"JD Smeijer","year":"2024","unstructured":"Smeijer JD, Wasehuus VS, Dhaun N, et al. Effects of zibotentan alone and in combination with dapagliflozin on fluid retention in patients with CKD. J Am Soc Nephrol. 2024;35(10):1381\u201390. https:\/\/doi.org\/10.1681\/ASN.0000000000000436.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"7909_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","volume":"21","author":"JD Smeijer","year":"2025","unstructured":"Smeijer JD, Kohan DE, Dhaun N, Noronha IL, Liew A, Heerspink HJL. Endothelin receptor antagonists in chronic kidney disease. Nat Rev Nephrol. 2025;21(3):175\u201388. https:\/\/doi.org\/10.1038\/s41581-024-00908-z.","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 1","key":"7909_CR23","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/ndt\/gfae214","volume":"40","author":"E Moedt","year":"2025","unstructured":"Moedt E, Wasehuus VS, Heerspink HJL. Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application. Nephrol Dial Transplant. 2025;40(Suppl 1):i37-46. https:\/\/doi.org\/10.1093\/ndt\/gfae214.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"7909_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jchf.2022.03.004","volume":"10","author":"JD Smeijer","year":"2022","unstructured":"Smeijer JD, Koomen J, Kohan DE, et al. Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure. JACC Heart Fail. 2022;10(7):498\u2013507. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.004.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"7909_CR25","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","volume":"95","author":"AA House","year":"2019","unstructured":"House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304\u201317. https:\/\/doi.org\/10.1016\/j.kint.2019.02.022.","journal-title":"Kidney Int"},{"issue":"16","key":"7909_CR26","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840\u201378. https:\/\/doi.org\/10.1161\/CIR.0000000000000664.","journal-title":"Circulation"},{"issue":"11","key":"7909_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/CS20240605","volume":"138","author":"P Ambery","year":"2024","unstructured":"Ambery P, Greasley PJ, Menzies RI, et al. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together? Clin Sci (Lond). 2024;138(11):687\u201397. https:\/\/doi.org\/10.1042\/CS20240605.","journal-title":"Clin Sci (Lond)"},{"issue":"10416","key":"7909_CR28","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Kiyosue A, Wheeler DC, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet. 2023;402(10416):2004\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(23)02230-4.","journal-title":"Lancet"},{"issue":"8","key":"7909_CR29","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.xkme.2024.100851","volume":"6","author":"M Madero","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6(8):100851. https:\/\/doi.org\/10.1016\/j.xkme.2024.100851.","journal-title":"Kidney Med"},{"issue":"2","key":"7909_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","volume":"99","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021;99(2):346\u20139. https:\/\/doi.org\/10.1016\/j.kint.2020.09.026.","journal-title":"Kidney Int"},{"issue":"8","key":"7909_CR31","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1111\/dom.16468","volume":"27","author":"V Wasehuus","year":"2025","unstructured":"Wasehuus V, Smeijer JD, Ambery P, et al. Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease. Diabetes Obes Metab. 2025;27(8):4311\u20139. https:\/\/doi.org\/10.1111\/dom.16468.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"7909_CR32","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.3390\/ijms24043427","volume":"24","author":"I Mart\u00ednez-D\u00edaz","year":"2023","unstructured":"Mart\u00ednez-D\u00edaz I, Martos N, Llorens-Cebri\u00e0 C, et al. Endothelin receptor antagonists in kidney disease. Int J Mol Sci. 2023;24(4):3427. https:\/\/doi.org\/10.3390\/ijms24043427.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"7909_CR33","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.3390\/jcm13206056","volume":"13","author":"A Rakotoarison","year":"2024","unstructured":"Rakotoarison A, Kepinska M, Konieczny A, et al. Endothelin inhibitors in chronic kidney disease: new treatment prospects. J Clin Med. 2024;13(20):6056. https:\/\/doi.org\/10.3390\/jcm13206056.","journal-title":"J Clin Med"},{"issue":"5","key":"7909_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ki.2009.203","volume":"76","author":"DE Kohan","year":"2009","unstructured":"Kohan DE. Biology of endothelin receptors in the collecting duct. Kidney Int. 2009;76(5):481\u20136. https:\/\/doi.org\/10.1038\/ki.2009.203.","journal-title":"Kidney Int"},{"issue":"2","key":"7909_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.116.234930","volume":"361","author":"M Vercauteren","year":"2017","unstructured":"Vercauteren M, Trensz F, Pasquali A, et al. Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J Pharmacol Exp Ther. 2017;361(2):322\u201333. https:\/\/doi.org\/10.1124\/jpet.116.234930.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"7909_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","volume":"9","author":"J Jensen","year":"2021","unstructured":"Jensen J, Omar M, Kistorp C, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2021;9(2):106\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(20)30382-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10417","key":"7909_CR37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Contreras G, Barratt J, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4.","journal-title":"Lancet"},{"issue":"10388","key":"7909_CR38","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(23)00569-X.","journal-title":"Lancet"},{"issue":"10367","key":"7909_CR39","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07909-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:03:06Z","timestamp":1794322986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7909"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07909-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}